This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

KT6-971

Kotobuki Pharmaceutical Co., Ltd.

Drug Names(s): KT6-971, S-556971

Description: KT6-971 is a cholesterol absorption inhibitor which was originally discovered by Kotobuki. The compound lowers the blood cholesterol level by selectively inhibiting a cholesterol transporter, Niemann-Pick C1-like 1 (NPC1L1) which is related to absorption of biliary and dietary cholesterol in the small intestine.

Deal Structure: Kotobuki and Shionogi
In October 2012, Kotobuki and Shionogi entered into a license agreement on the worldwide rights of development, manufacturing and commercialization of KT6-971 which has been developed by Kotobuki in Japan. Under the terms of the agreement, Shionogi will pay an upfront payment, milestone payments at successful completion of key development plans, and royalties based on net sales to Kotobuki. In August 2015, Shionogi announced that it returned rights for S-556971 back to Kotobuki.


KT6-971 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug